Hagop Kantarjian

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells
    Nada Orsolic
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Sci 97:952-60. 2006
  2. ncbi BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices
    Hagop Kantarjian
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 6:S37-42; quiz S43-S44. 2008
  3. ncbi Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
  4. doi Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
    Alfonso Quintas-Cardama
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6315-21. 2009
  5. ncbi Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2099-108. 2005
  6. ncbi Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
  7. ncbi Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy
    Gloria N Mattiuzzi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:581-9. 2004
  8. ncbi A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1234-41. 2003
  9. ncbi Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
  10. doi Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
    Arturo Vega-Ruiz
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 32:1468-71. 2008

Collaborators

Detail Information

Publications116 found, 100 shown here

  1. ncbi Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells
    Nada Orsolic
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Sci 97:952-60. 2006
    ..In conclusion, adaphostin showed significant and selective activity against CML and AML cells and its development for clinical testing is warranted...
  2. ncbi BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices
    Hagop Kantarjian
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 6:S37-42; quiz S43-S44. 2008
    ..Identifying patients in whom a change to dasatinib or nilotinib is more appropriate than imatinib dose escalation is therefore important...
  3. ncbi Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
    Apostolia Tsimberidou
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Leuk Res 27:893-7. 2003
    ..CSA inclusion in gemtuzumab ozogamicin-based regimens is feasible. MFAC is an effective regimen for refractory AML...
  4. doi Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
    Alfonso Quintas-Cardama
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Blood 113:6315-21. 2009
    ..This risk is discernible as early as 3 months into imatinib therapy by molecular analysis and may provide the rationale to institute therapies that render higher rates of early response...
  5. ncbi Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:2099-108. 2005
    ..The objectives of this study were to update the long-term experience with imatinib in patients who had accelerated-phase CML and to compare outcomes with historic experience...
  6. ncbi Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
    Deborah A Thomas
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 106:1569-80. 2006
    ..Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens...
  7. ncbi Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy
    Gloria N Mattiuzzi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:581-9. 2004
    ..A prospective historical control study evaluated the efficacy and safety of amphotericin B lipid complex (ABLC) in this patient population...
  8. ncbi A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1234-41. 2003
    ....
  9. ncbi Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 103:4396-407. 2004
    ..Molecular CRs were achieved in both groups (SCT or no SCT). Outcome with hyper-CVAD and imatinib mesylate appears better than with prior regimens; continued accrual and longer follow-up of the current cohort is needed...
  10. doi Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
    Arturo Vega-Ruiz
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Res 32:1468-71. 2008
    ..The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL...
  11. doi Current and future management options for myelodysplastic syndromes
    Jeffrey Bryan
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 70:1381-94. 2010
    ..This review focuses on supportive care modalities, the approved agents indicated for the treatment of MDS and future directions for the treatment of MDS, including agents under clinical investigation...
  12. pmc Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
    Naveen Pemmaraju
    Department of Leukemia, University of Texas, Anderson Cancer Center, Houston, TX 77230, USA
    Haematologica 97:1029-35. 2012
    ..Outcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment. However, little is known about outcomes of chronic myeloid leukemia in adolescent and young adult patients...
  13. doi Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
    Aziz Nazha
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Am J Hematol 88:961-6. 2013
    ..In multivariate analysis, CIA retained its favorable impact on OS compared to IA. Thus, CIA is an effective and safe therapy for patients ≤60 years with newly diagnosed AML...
  14. ncbi Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
    Hagop Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer, Houston, Texas 77030, USA
    Cancer 112:837-45. 2008
    ..Response rates in chronic myeloid leukemia (CML) are now reported based on the cumulative incidence of a single-time best response. The study aim was to examine the significance of different response criteria for CML on imatinib therapy...
  15. ncbi Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
    Alfonso Quintas-Cardama
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:248-55. 2007
    ..Homoharringtonine (HHT) is a cephalotaxus alkaloid that inhibits the synthesis of proteins leading to apoptosis. Intravenous HHT has demonstrated activity in patients with chronic myeloid leukemia (CML) after failure with interferon...
  16. doi A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
    Elias Jabbour
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:1236-44. 2011
    ..The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome...
  17. doi Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Constantine S Tam
    Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 27:5587-93. 2009
    ..We aimed to define an accelerated phase (AP) in MF by characterizing disease features that can identify patients with median overall survival of <or= 12 months at any time in the disease course...
  18. doi MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells
    Mirna Golemovic
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Invest New Drugs 28:402-12. 2010
    ..This agent, therefore, combines low in vivo toxicity with formidable in vitro pro-apoptotic ROS-mediated activity, and may represent a novel OAD suitable for clinical development against a variety of hematological malignancies...
  19. ncbi Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
    Stefan Faderl
    Department of Leukemia, Box 428, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 105:940-7. 2005
    ..The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy...
  20. ncbi Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 11:7817-24. 2005
    ..A phase I study of cloretazine combined with cytarabine (1-beta-d-arabinofuranosylcytosine, ara-C) was conducted in patients with refractory disease...
  21. doi Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
    Farhad Ravandi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 27:504-10. 2009
    ....
  22. ncbi Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome
    Srdan Verstovsek
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 118:151-6. 2002
    ..These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS...
  23. ncbi Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 107:480-2. 2006
    ..SBT is still a rare event, probably less common than that observed with IFN-alpha therapy. Continuous monitoring of patients treated with imatinib is mandatory...
  24. ncbi Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 10:68-75. 2004
    ..Multivariate analyses were conducted to assess the independent prognostic effect of therapy (imatinib versus other) on survival...
  25. pmc Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
    Elias Jabbour
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 12:244-51. 2012
    ..The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies...
  26. doi Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Blood 120:4840-5. 2012
    ..The studies reviewed are registered at www.clinicaltrials.gov as 2009-0172 (NCT00926731) and 2009-0217 (NCT00952588)...
  27. ncbi Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Blood 109:52-7. 2007
    ..We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS...
  28. ncbi Biphenotypic acute leukaemia: a case series
    Ahmed Aribi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston TX 77030, USA
    Br J Haematol 138:213-6. 2007
    ..Seven patients were treated with regimens designed for AML. Complete remission (CR) rates of 78% and 57% were noted respectively. The overall survival probability at 2 years was 60%...
  29. doi Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
    Farhad Ravandi
    Departments of Leukemia, Hematopathology, Biostatistics, Infectious Diseases, and Lymphoma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5425-30. 2009
    ..To examine the efficacy and safety of the combination of alemtuzumab and pentostatin in patients with T-cell neoplasms...
  30. ncbi Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
    Hagop Kantarjian
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 106:1099-109. 2006
    ..Topotecan-cytarabine regimens have shown encouraging results in higher-risk MDS. The aim of this study was to analyze the long-term results with topotecan-cytarabine versus other intensive chemotherapy regimens in higher-risk MDS...
  31. ncbi Outcome of patients with acute myelogenous leukemia after second salvage therapy
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, PO Box 301402, Houston, TX 77230 1402, USA
    Cancer 104:547-54. 2005
    ..The authors analyzed the outcome of patients with AML undergoing second salvage therapy, and identified prognostic factors associated with response and survival...
  32. ncbi Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:2788-801. 2004
    ..The current analysis updated the long-term results with the original hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) program, with a median follow-up time of 63 months...
  33. ncbi Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy
    Gloria N Mattiuzzi
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 100:568-73. 2004
    ..v. ITRA) reduced the incidence of probable/proven fungal infections in this group of patients, and compare the results with those of a historic control group treated with fluconazole plus itraconazole capsules (F+I)...
  34. doi Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia
    Aref Al-Kali
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma Leuk 11:361-6. 2011
    ..Sorafenib is an orally active multikinase inhibitor with potent activity against FLT3 and the Raf/ERK/MEK kinase pathway...
  35. pmc Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
    Hagop Kantarjian
    Department of Leukemia, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 119:1981-7. 2012
    ..Imatinib therapy minimized the impact of known prognostic factors and Sokal risk in CP-CML and accentuated the impact of age in AP- and BP-CML...
  36. ncbi Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1295-302. 2007
    ..Lonafarnib can inhibit the proliferation of imatinib-resistant cells and increases imatinib-induced apoptosis in vitro in cells from imatinib-resistant patients...
  37. doi Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 117:1822-7. 2011
    ..This scoring system could serve to advise patients of their prognosis and treatment options, as well as to evaluate the benefit of newer alternate options...
  38. ncbi Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase
    Hagop Kantarjian
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 98:1430-7. 2003
    ..The objective of the current study was to evaluate the benefit of adding imatinib to the treatment sequence of patients with early chronic phase Ph-positive CML who received interferon alpha (IFN)-based regimens as frontline therapy...
  39. ncbi Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Leuk Res 30:1499-505. 2006
    ..In addition, both drugs inhibited the phosphorylation of PDGFR-alpha tyrosine kinase with equivalent efficacy. We conclude that AMN107 and imatinib are active and equipotent against cells expressing the FIP1L1-PDGFR-alpha fusion gene...
  40. ncbi Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience
    Bryan Hennessy
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 77:209-14. 2004
    ..SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed...
  41. doi Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
    Michael S Mathisen
    Department of Leukemia, MD Anderson Cancer Center, Houston, TX 77005, USA
    Clin Lymphoma Myeloma Leuk 13:139-43. 2013
    ..Other transplant-specific outcomes, including overall survival (OS), were also similar when compared with the control group...
  42. ncbi Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    William Wierda
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:4070-8. 2005
    ..The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response...
  43. doi Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial
    Maria E Cabanillas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:848-55. 2012
    ....
  44. doi Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen
    Deborah Thomas
    Department of Leukemia, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:4580-9. 2010
    ..5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome...
  45. ncbi Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, P O Box 428, Houston, TX 77030, USA
    Leuk Res 27:661-9. 2003
    ..In contrast, high VEGF-R1 levels did not correlate with a specific CML phase, characteristic, or outcome. Our findings support VEGF-R2 over-expression as an independent prognostic indicator for shortened survival in patients with CML...
  46. doi Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
    Xavier C Badoux
    Departments of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Blood 118:2085-93. 2011
    ..Although CFAR produced good response rates in this highly pretreated high-risk group of patients, there was no benefit in survival outcomes...
  47. ncbi Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
    Jorge Cortes
    The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    J Clin Oncol 23:2805-12. 2005
    ..To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS)...
  48. ncbi Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
    Deborah A Thomas
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 123:436-41. 2003
    ..Thalidomide analogues with more potent immunomodulatory activities and more favourable toxicity profiles may offer more promise as anti-AML therapy...
  49. ncbi Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2000-6. 2007
    ....
  50. doi Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:53-5. 2008
    ..Although the T315I mutation is resistant to currently available TKIs, survival of patients with T315I remains mostly dependent on the stage of the disease, with many CP patients having an indolent course...
  51. pmc Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
    Gautam Borthakur
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Haematologica 96:62-8. 2011
    ..A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias...
  52. doi Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
    Constantine S Tam
    Leukemia Department, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:516-8. 2008
    ..These results suggest that patients receiving 2TKI with no cytogenetic response at 3 to 6 months should be considered for alternative therapies...
  53. doi Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib
    Manish Sharma
    Department of Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Biol Blood Marrow Transplant 17:1874-7. 2011
    ..Sorafenib is not effective in the treatment of FLT3-ITD-positive AML relapsing after HSCT. Preventive strategies after HSCT may be more suitable for these high-risk patients...
  54. ncbi Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
    Jorge Cortes
    Departments of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3425-32. 2005
    ..To determine the clinical significance of molecular response and relapse among patients with chronic myelogenous leukemia (CML) treated with imatinib...
  55. doi Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:1478-84. 2010
    ..In conclusion, a significant number of CD34+ cells can be safely collected in patients with CML who are on imatinib therapy, but CD34+ cell yields improve when imatinib is temporarily withheld...
  56. doi Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
    Koichi Takahashi
    Divison of Cancer Medicine, MD Anderson Cancer Center, The University of Texas, Houston, TX 77030 4009, USA
    Br J Haematol 161:659-66. 2013
    ..Incorporating FLT3i into salvage strategies may improve long-term outcome of patients with AML FLT3-ITD. Prospective studies to validate this conclusion are warranted...
  57. doi Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study
    Elias Jabbour
    Department of Stem Cell Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 88:198-200. 2013
    ..001). These results would suggest that prospective studies are needed to delineate the timing and efficacy of allo-SCT in the HMA era...
  58. doi Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system
    Wei Gang Tong
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Cancer 118:4462-70. 2012
    ..Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS...
  59. ncbi Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
    Elihu Estey
    Department of Leukemia, University of Texas M D Anderson Cancer Center, 1515 Holcombe, Box 428, Houston, 77030, USA
    Blood 107:3469-73. 2006
    ..ATRA plus ATO may serve as an alternative to chemotherapy in low-risk untreated APL (eg, in older patients) and, when combined with GO, may improve outcome in high-risk patients...
  60. doi Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
    Constantine S Tam
    Departments ofLeukemia, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 112:975-80. 2008
    ..5% per year for the third year onward. In a multivariate analysis of patients receiving fludarabine-based therapy at our center, FCR therapy emerged as the strongest independent determinant of survival...
  61. pmc BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias
    Dan Jones
    Departments of Hematopathology, University of Texas M D Anderson Cancer Center, Houston, USA
    Blood 112:5190-2. 2008
    ..Therefore, higher kinase activity by mutation, transcriptional up-regulation or gene amplification appears required for lymphoid transformation by p210 BCR-ABL...
  62. ncbi The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia
    Francis J Giles
    Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 136:624-7. 2007
    ..001) respectively; median OS was 45, 31 and 19 weeks (P = 0.04) respectively. The HCTCI score is predictive of early death rates and OS in older patients receiving AML induction therapy...
  63. ncbi A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:2908-17. 2004
    ..As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS)...
  64. ncbi AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
    Mirna Golemovic
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:4941-7. 2005
    ..These results strongly support investigation of the clinical efficacy of AMN107 in patients with CML...
  65. ncbi Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
    Francis Giles
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, 77230 1402, USA
    Br J Haematol 134:58-60. 2006
    ..The EPI is reproducible and useful...
  66. ncbi Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
    Efrosyni Apostolidou
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, Box 428, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Leuk Res 27:887-91. 2003
    ..The inclusion of CSA in a gemtuzumab ozogamicin-containing regimen is feasible. The MDAC regimen was associated with significant toxicity in a cohort of patients with very advanced AML...
  67. ncbi T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years
    Ahmed Aribi
    Department of Leukemia, Unit 428, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Leuk Res 31:939-45. 2007
    ..Significant responses were not seen with any of these treatment regimens. We conclude that cyclosporine therapy may be beneficial for T-LGL leukemia patients. New treatment modalities are needed for these patients...
  68. ncbi Phase I study of bortezomib in refractory or relapsed acute leukemias
    Jorge Cortes
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3371-6. 2004
    ..The in vitro evidence of antileukemia and transient hematological improvements observed in some patients warrants further investigation of bortezomib in acute leukemias, probably in combination with other agents...
  69. ncbi Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Deborah A Thomas
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 428, Houston, TX 77030, USA
    Blood 104:1624-30. 2004
    ..Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease...
  70. doi Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
    Fabio P S Santos
    Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 150:303-12. 2010
    ..Further studies are required to determine whether there might be a minimum adequate dose of these agents...
  71. ncbi Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
    Susan O'Brien
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 111:1816-9. 2008
    ..004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770...
  72. ncbi AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
    Srdan Verstovsek
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, 77230, USA
    Cancer 104:1230-6. 2005
    ..Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response...
  73. doi Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    Jorge E Romaguera
    Department of Lymphoma Myeloma, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 150:200-8. 2010
    ..We conclude that intense chemoimmunotherapy without stem cell transplantation is effective for untreated aggressive MCL...
  74. doi First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
    Farhad Ravandi
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 116:2070-7. 2010
    ..The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph(+) ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793...
  75. doi Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
    Yiming Chen
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 29:2507-13. 2011
    ....
  76. ncbi Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome
    Raymond Lai
    Department of Hematopathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 94:14-7. 2002
    ..Endostatin, a C-terminal fragment of collagen XVIII, is an endogenous angiogenesis inhibitor. While endostatin is being investigated for its usefulness in treating solid tumors, its significance in hematologic malignancies is unknown...
  77. ncbi Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
    Nada Orsolic
    Department of Leukemia, M D Anderson Cancer Center, The University of Texas, Houston 77030 4009, USA
    Br J Haematol 124:727-38. 2004
    ..These data indicate that the combination of troxacitabine and IM has significant preclinical activity in advanced CML and that clinical evaluation of this combination is warranted...
  78. ncbi Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
    Maurizio Zangari
    University of Arkansas for Medical Sciences, The Multiple Myeloma Institute for Research and Therapy, Little Rock, Arkansas, USA
    Clin Cancer Res 10:88-95. 2004
    ..SU5416 is a small molecule VEGF receptor 2 inhibitor. Experimental Design: Adult patients with advanced MM were entered on a multicenter phase II study...
  79. ncbi Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Blood 108:1809-20. 2006
    ..The importance of regular monitoring at experienced centers was highlighted...
  80. ncbi Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience
    Guillermo Lazo
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:2218-24. 2003
    ..It has been reported that arsenic trioxide (As(2)O(3)) is effective in this setting. The authors report the experience of The M. D. Anderson Cancer Center with As(2)O(3) in the treatment of patients with recurrent APL...
  81. ncbi Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
    B Douglas Smith
    Departments of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Blood 103:3669-76. 2004
    ..Our results show that FLT3 inhibition is associated with clinical activity in AML patients harboring FLT3-activating mutations and indicate that CEP-701 holds promise as a novel, molecularly targeted therapy for this disease...
  82. ncbi Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia
    Srdan Verstovsek
    Department of Leukemia and Hematopathology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 72, Houston, TX 77030, USA
    Blood 99:2265-7. 2002
    ..008). Multivariate analysis showed that VEGF was not independent of the synthesis stage (P =.09). These data suggest that VEGF plays a role in the biology of CML and that VEGF inhibitors should be investigated in CML...
  83. ncbi Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy
    Ehab Atallah
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:2996-9. 2002
    ..Standard therapy for such patients is undetermined. Imatinib mesylate, a Bcr-Abl tyrosine kinase inhibitor, has shown activity in CML...
  84. ncbi Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
    Patricia Ault
    Department of Leukemia, M D Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA
    Leuk Res 26:881-4. 2002
    ..The possible mechanism of response is discussed. This observation may lead to a better understanding of the pathophysiology of HES, and may provide a new form of effective therapy for the disease...
  85. ncbi Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome
    Francis Giles
    Department of Leukemia, University of Texas, M D Anderson Cancer Center, Houston 77030, USA
    Acta Haematol 108:164-7. 2002
  86. ncbi Differences in CD33 intensity between various myeloid neoplasms
    Iman Jilani
    Department of Hematopathology, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Am J Clin Pathol 118:560-6. 2002
    ..There was no correlation between CD33 intensity and response to therapy or overall survival in 35 patients treated with protocols including Mylotarg. These data demonstrate variation in CD33 intensity between various leukemias...
  87. ncbi Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
    Jorge Cortes
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1400 Holcombe Boulevard, Houston, Texas 77030, USA
    Cancer Chemother Pharmacol 50:497-500. 2002
    ..Topotecan and cytarabine (ara-C) is an effective anti-AML regimen. A pilot study of Mylotarg combined with topotecan and ara-C (MTA) was conducted in patients with refractory AML...
  88. ncbi Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
    Yesid Alvarado
    Department of Leukemia, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA
    Cancer Chemother Pharmacol 51:87-90. 2003
    ..A combination of an anthracycline and cytarabine (ara-C) is the core of most AML induction regimens. We conducted a pilot study of Mylotarg combined with idarubicin and ara-C in patients with refractory or relapsed AML...
  89. ncbi Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
    Apostolia Tsimberidou
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 97:1481-7. 2003
    ....
  90. ncbi Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    Stephen G O'Brien
    University of Newcastle, Newcastle, United Kingdom
    N Engl J Med 348:994-1004. 2003
    ..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML...
  91. ncbi Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML
    Elihu Estey
    Department of Leukemia, MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA
    Leuk Res 27:475-9. 2003
    ..These data suggest that the minimum needed to declare CR in AML be changed from 1500 to 1000...
  92. ncbi Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 45:2187-95. 2004
    ..Ongoing studies will better determine their mechanism of action and the role of combination with other agents, defining their place in the therapeutic arsenal of hematologic disorders...
  93. ncbi Clofarabine in adult acute leukemias: clinical success and pharmacokinetics
    Todd Cooper
    Department of Experimental Therapeutics, UT M D Anderson Cancer Center, Houston, Texas, USA
    Nucleosides Nucleotides Nucleic Acids 23:1417-23. 2004
    ..In conclusion, clofarabine is an active agent in the treatment of acute leukemias and MDS, and cellular pharmacokinetics has prognostic significance...
  94. ncbi A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
    Francis Giles
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Cancer Res 12:4628-35. 2006
    ..LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle...
  95. ncbi The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells
    Michael W N Deininger
    Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon 97239, USA
    Cancer 110:1509-19. 2007
    ..In some patients, CCA/Ph-negative status was associated with myelodysplasia or acute myeloid leukemia. The objective of the current study was to determine the prognostic impact of CCA/Ph-negative cells...
  96. ncbi Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  97. ncbi Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:653-62; discussion 663-4, 667-8. 2007
    ..Combination strategies are currently being investigated in preliminary clinical studies and may prove to be useful. Overall, there are an increasing number of treatment options now available for patients with CML...
  98. ncbi Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406
    Jingxuan Pan
    Department of Leukemia, The University of Texas, Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Sci 98:1223-5. 2007
    ..In contrast, neither drug was effective against HMC-1.2 cells at the dose range tested. The present results suggest clinical potential for INNO-406 in KIT V560G-expressing malignancies...
  99. ncbi Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges
    Elias Jabbour
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma Myeloma 7:S51-7. 2007
    ..The outlook today for patients with CML is much brighter than that of a few years ago...
  100. ncbi A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase
    Alfonso Quintas-Cardama
    Department of Leukemia, The University of Texas M D Anderson Cancer Center Houston, TX 77030, USA
    Leuk Lymphoma 48:283-9. 2007
    ..Median survival was 5 months (range, 2 - 20 months). This outpatient regimen is effective and well tolerated and perhaps superior to single-agent imatinib for patients in myeloid BP...
  101. ncbi Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia
    Wanlong Ma
    Quest Diagnostics Nichols Institute 33608 Ortega Highway, Rm 108B, San Juan Capistrano, CA 92690 6130, USA
    Haematologica 92:170-5. 2007
    ..Peripheral blood plasma was analyzed in this study because of previous detection of nucleic acids and proteins from tumor cells in plasma samples...